Dr. Salim Dhanji reports

ME THERAPEUTICS ENGAGES ORBITON FINANCIAL FOR INVESTOR AWARENESS

ME Therapeutics Holdings Inc. has engaged Orbiton Financial Inc. to provide investor relations and market awareness services to the company.

Orbiton will assist ME Therapeutics in enhancing investor communications and awareness of its in vivo chimeric antigen receptor and therapeutic mRNA research and development activities, as well as continuing corporate development activities. The engagement comes as the company continues working to advance its in vivo dual targeted CAR toward a first-in-human clinical trial and execute its strategy to secure a potential listing on the Nasdaq exchange.

The services will be performed by Matthew Nelson, who will serve in the consulting role of vice-president, investor relations, on a non-employee, non-officer basis. Orbiton and Mr. Nelson are at arm's length to the company.

Mr. Nelson is chief operating officer of Orbiton, an artificial-intelligence-native investor relations platform serving public issuers across North America. He has worked extensively with TSX Venture Exchange-listed issuers, advising on investor engagement and regulatory-compliant communications under Canadian securities requirements. He has a particular interest in modernizing investor outreach and applying technology and data-driven tools to broaden shareholder reach and deepen market engagement.

"The in vivo CAR space continues to generate excitement in the scientific community evidenced by several recent deals in the space. We are now planning to prioritize generating market awareness as we continue towards a first-in-human clinical trial," said Dr. Salim Dhanji, PhD, chief executive officer of ME Therapeutics.

Under the agreement, Orbiton will lead the company's investor relations program, including developing its investor relations strategy, preparing investor communications and website investor content, and co-ordinating investor meetings, road shows and conferences. These activities will be conducted through Instagram, LinkedIn and X (formerly Twitter). The agreement was signed on Nov. 5, 2026, and is effective Nov. 3, 2026, for an initial period of 12 months, continuing month to month thereafter, and may be terminated by either party on 30 days notice. In consideration for these services, Orbiton will be paid $2,800 (U.S.) per month plus preapproved expenses. In addition, Mr. Nelson has been granted options to purchase 125,000 common shares of the company at an exercise price of $1.05 per common share until Nov. 5, 2028, vesting monthly over 12 months. Aside from these options, neither Orbiton nor any of its principals currently hold an interest, directly or indirectly, in the securities of the company. There are no performance factors contained in the agreement.

About ME Therapeutics Holdings Inc.

ME Therapeutics is a publicly listed biotechnology company based in Vancouver focused on developing novel therapeutics designed to reprogram immune cells in vivo to reshape the tumour microenvironment and to directly recognize and kill cancer cells.

We seek Safe Harbor.